T. Rowe Price Associates’s Zevra Therapeutics ZVRA Stock Holding History

T. Rowe Price Associates’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$407K	Buy	43,616 +11,476	+36%	+$103K	﹤0.01%	2540
2025 Q4	$288K	Buy	32,140 +3,648	+13%	+$34.5K	﹤0.01%	2663
2025 Q3	$271K	Buy	28,492 +2,802	+11%	+$28.1K	﹤0.01%	2652
2025 Q2	$227K	Buy	25,690 +3,005	+13%	+$24.4K	﹤0.01%	2660
2025 Q1	$170K	Buy	22,685 +2,120	+10%	+$16.8K	﹤0.01%	2707
2024 Q4	$172K	Buy	20,565 +6,966	+51%	+$59.5K	﹤0.01%	2741
2024 Q3	$95K	Hold	13,599	–	–	﹤0.01%	2828
2024 Q2	$67K	Buy	13,599 +2,588	+24%	+$12.3K	﹤0.01%	2816
2024 Q1	$64K	Buy	+11,011	New	+$67.7K	﹤0.01%	2841

Other funds holding ZVRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

T. Rowe Price Associates's ZVRA Position: Q1 2026 in Review

T. Rowe Price Associates increased its Zevra Therapeutics (ZVRA) stake by 36% in Q1 2026, buying an estimated $103K and bringing the position to 43,616 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #2540.

T. Rowe Price Associates first reported a position in ZVRA in Q1 2024 and has held it in 9 quarters since. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

T. Rowe Price Associates held 43,616 shares of Zevra Therapeutics worth $407K as of Q1 2026.
T. Rowe Price Associates bought 11,476 Zevra Therapeutics shares in Q1 2026, an estimated $103K.
Zevra Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2540 holding.
T. Rowe Price Associates first reported a position in Zevra Therapeutics in Q1 2024 and has held it in 9 quarters since.
148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.